Latest News

The present study retrospectively evaluated the efficacy and safety of enzalutamide in different lines of metastatic castration-resistant prostate cancer (mCRPC) treatment in a real-world setting. The clinical records of patients with mCRPC treated with enzalutamide between August 2015 and October 2017 were retrieved from all 7 public oncology centers in Hong Kong and reviewed. The […]

A Phase 1, Open-label, First-in-human, Multi-center, Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of a Thorium-227 Labeled Antibody-chelator Conjugate, BAY 2315497 Injection, in Patients With Metastatic Castration Resistant Prostate Cancer Condition: Metastatic Castration Resistant Prostate Cancer (mCRPC) Intervention: Drug: BAY 2315497 Injection Purpose: The study medication (BAY 2315497 Injection) is a thorium-227 […]

To describe study design and procedures for a prospective randomized trial investigating whether radical prostatectomy (RP) ± radiation improves cause-specific survival in comparison with primary radiation treatment (RT) and androgen deprivation treatment (ADT) in patients with locally advanced prostate cancer (LAPC). SPCG-15 is a prospective, multi-centre, open randomized phase III trial. Patients are randomized to either standard […]

Advanced prostate cancer initially responds to androgen deprivation therapy (ADT), but the disease inevitably recurs as castration-resistant prostate cancer (CRPC). Although CRPC initially responds to abiraterone and enzalutamide, the disease invariably becomes nonresponsive to these agents. Novel approaches are required to circumvent resistance pathways and to extend survival, but the mechanisms underlying resistance remain poorly […]

{{header-clinical-trials-navigation}} Multimodality Therapy With Induction Carboplatin/Nab-Paclitaxel/Durvalumab Followed by Surgical Resection and Risk-adapted Adjuvant Therapy for the Treatment of Locally-Advanced and Surgically Resectable Squamous Cell Carcinoma of the Head and Neck Condition: Carcinoma, Squamous Cell, Oral Cancer, Oropharynx Cancer, Larynx Cancer, Lip Cancer, Esophageal Cancer Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03174275 Sponsor: UNC […]

{{header-clinical-trials-navigation}} Male Fertility Preservation Using Cryopreservation of Testicular Tissue Before Highly Gonadotoxic Cancer Treatment Condition: Childhood Cancer, Fertility Disorders Study Type: Interventional Clinical Trials Identifier NCT 8-digits: NCT03180918 Sponsor: Gumy-Pause Fabienne Eligibility: Age: minimum 3 Months maximum 18 Years Gender: Male Inclusion Criteria: Prepubertal patients aged 3 months and older Peri and pubertal patients after […]

{{header-clinical-trials-navigation}} Vascular Fingerprint to Identify Patients at Risk for Arterial Cardiovascular Events Within the First Year After Start of Cisplatin-based Chemotherapy for Testicular Cancer: a Validation Study Condition: Testicular Cancer Study Type: Observational Clinical Trials Identifier NCT 8-digits: NCT02573584 Sponsor: University Medical Center Groningen Phase: Eligibility: Age: minimum 18 Years maximum 50 Years Gender: Male […]

Salvage lymph node dissection (SLND) represents a possible treatment option for prostate cancer patients affected by nodal recurrence after local treatment. However, SLND may be associated with intra- and postoperative complications, and the oncological benefit may be limited to specific groups of patients. To identify the optimal candidates for SLND based on preoperative characteristics. The […]

The concept of metastasis-directed therapy for nodal oligorecurrences with stereotactic body radiotherapy is increasingly accepted. Hence, the comparison between salvage extended field radiotherapy (s-EFRT) and salvage involved field radiotherapy (s-IFRT) in patients with 18F-fluorocholine (FCH) PET/CT+ nodal oligorecurrences from prostate cancer is worthy of investigation. Patients with oligorecurrent nodes on FCH PET/CT treated with salvage […]

For men in the United States, prostate cancer is not only the most common cancer but also the second leading cause of cancer-associated death. Advanced prostate cancer can metastasize to several different organ systems including the lymph nodes, bones, lungs, and visceral organs. Prognosis for metastatic prostate cancer is poor with the relative 5-year survival […]